Meditope Biosciences Gets $3.6M For Cancer Treatments

Los Angeles-based Meditope Biosciences announced this morning that it has raised $3.6M in a Series A financing, to accelerate development of its antibody-based cancer products. The startup said the investment came from angel investors. Meditope Biosciences is headed by Stephanie Hsieh, and says it is developing proprietary monocolonal antibody (mAb) linker technology. Meditope's technology was originally developed at the City of Hope Cancer Center. As part of the funding round, the company also said it has named Elisabeth Gardiner, Ph.D., as its Chief Scientific Officer. Gardiner previously was at aTyr Pharma and the Genomics Institute of the Novartis Research Foundation. More information »